MedTrace Logo

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

NCT00220272 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2008-12-23

No results posted yet for this study

Summary

* The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging.
* Secondary objectives are to assess the effect of SR57667B on symptomatic decline in patients with early PD, to assess the safety/tolerability of SR57667B in patients with early PD and to document plasma concentrations of SR57667 in patients with early PD.

Conditions

  • Parkinson Disease

Interventions

DRUG

SR57667B

Sponsors & Collaborators

Principal Investigators

  • Philippe Remy, MD · Service Hospitalier Frédéric Joliot, CEA, Orsay France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • Canada
  • Finland
  • France
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220272 on ClinicalTrials.gov